This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: MitraClip

October 2018 Br J Cardiol 2018;25:135–7 Online First

European Society of Cardiology 2018 Congress in briefs

BJC Staff

Abstract

European Society of Cardiology congress 2018, held in Munich Other news from the European Society of Cardiology Congress 2018 Not all HDL cholesterol is cardioprotective COMMANDER HF: rivaroxaban in heart failure… …and in VTE in the MARINER trial Is it safe for women with heart disease to become pregnant? Several new guidelines from the ESC were announced at the meeting: ESC guidelines on the management of cardiovascular diseases during pregnancy, first published in 2011, have been updated with a second edition in 2018 2018 ESC/EACTS (European Association for Cardio-Thoracic Surgery) guidelines on myocardial revascularisation 2018 ES

| Full text

May 2018 Br J Cardiol 2018;25:63–8 doi:10.5837/bjc.2018.014 Online First

3D echocardiography: benefits and steps to wider implementation

Kevin Cheng, Mark J Monaghan, Antoinette Kenny, Bushra Rana, Rick Steeds, Claire Mackay, DeWet van der Westhuizen

Abstract

Chamber dimensions and function: superior endocardial visualisation and freedom from geometric modelling Left ventricular volume and function The majority of echocardiographic studies are performed to investigate left ventricular (LV) chamber dimensions and LV ejection fraction (LVEF).1 Current methods via two-dimensional (2D) echocardiography (2DE) are operator-dependent, relying on the visual interpretation of moving images, and succumb to inter- and intra-observer variability and poor test–retest reliability.2-4 To calculate a volume, geometric modelling of chamber shape must be performed and consequently, LVEF estimation from 2DE is sub

| Full text

March 2016 Br J Cardiol 2016;23:21–6 doi:10.5837/bjc.2016.009

Advances in transcatheter options in the management of mitral valve disease

Mamta H Buch

Abstract

Introduction Dr Mamta Buch, University Hospital of South Manchester NHS Foundation Trust Mitral regurgitation (MR) is increasingly prevalent in developed countries and represents a significant cause of morbidity and mortality. It affects 24% of adults with valvular heart disease and is present in 7% of the population over the age of 75 years.1,2 Significant MR is a complex condition and, left untreated, it leads to slow progressive deterioration. Up to 50% of patients with criteria for surgical intervention are not referred for surgery, largely due to advanced age, significant comorbidities and the presence of left ventricular (LV) dysfunctio

| Full text

November 2012 Br J Cardiol 2012;19:152

News from the ESC Congress 2012

BJCardio Staff

Abstract

WOEST: aspirin not required for stent patients on oral anticoagulants  A strategy of using clopidogrel as a single antiplatelet drug for patients receiving a drug-eluting stent who are also taking an oral anticoagulant appears safe and can reduce bleeding, the results of the WOEST study suggest. How to treat patients on anticoagulation when they receive a stent is fraught with difficulty as giving the normal dual antiplatelet therapy with aspirin and clopidogrel means they will be taking three anti-clotting agents which could increase bleeding complications to a dangerous level. But no randomised clinical trials have ever investigated whethe

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now